Cerebrolysin
Well StudiedPurified porcine brain proteins
Cerebrolysin is a mixture of neurotrophic peptides and amino acids derived from porcine brain tissue. It has been studied in neuroscience research for its effects on neuronal survival, neurotrophic factor expression, and neuroplasticity. Published research has investigated its neuroprotective properties in various laboratory models. RaysunPeptide supplies Cerebrolysin for qualified research and laboratory applications.
Mechanism of Action
IV/IM administration provides optimal bioavailability and brain penetration of neuropeptides and neurotrophic factors.
Key Benefits
Molecular Data
Dosing Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Small Volume IV | Up to 10mL | Once daily | Undiluted IV slow push over 3 minutes |
| Intramuscular | Up to 5mL | Once daily | Undiluted IM injection over 3 minutes |
| Acute Stroke | 20-50mL | Once daily for 10-21 days | IV infusion (diluted to 100mL minimum) |
| Traumatic Brain Injury | 20-50mL | Once daily for 7-30 days | IV infusion (diluted to 100mL minimum) |
| Alzheimer's Disease | 10-30mL | 5 days weekly for 4 weeks | IV injection/infusion (2-4 cycles yearly) |
| Vascular Dementia | 10-30mL | 5 days weekly for 4 weeks | IV injection/infusion (2-4 cycles yearly) |
Research Indications
Cognitive
Meta-analyses show modest cognitive improvements, though clinical significance remains debated.
Multiple RCTs demonstrate significant ADAS-cog and CIBIC+ improvements.
Large meta-analysis shows significant NIHSS improvements; other studies found no functional benefit.
Neuroprotection
Largest meta-analysis (1,879 patients) shows NIHSS benefits; independent analysis found no mRS improvement.
Multiple trials including CAPTAIN series confirm GCS/GOS improvements.
Pilot trial shows promising 6-month outcomes; requires larger confirmatory studies.
Recovery
Some studies show enhanced recovery; results vary significantly between trials.
Early administration within 72 hours shows better outcomes than delayed treatment.
Peptide Interactions
Safe combination with no significant interactions; both support cognitive function.
No interactions reported; may have synergistic cognitive effects in Alzheimer's treatment.
Potential additive neurotropic effects; monitor for enhanced antidepressant effects.
May have additive neurological effects; requires careful monitoring.
Contraindicated per prescribing information; do not mix in same infusion.
Should not be mixed in same IV infusion per official guidelines.
Compatibility issues; do not mix in same IV infusion.
Both enhance neurotrophic factors; potential additive effects—start with lower doses.
What to Expect
Side Effects & Safety
Common (Generally Mild)
- •Generally well tolerated
- •Possible mild dizziness or agitation in early treatment
Stop Signs (Seek Medical Attention)
- ⚠Severe allergic reactions (anaphylaxis, severe rash)
- ⚠New onset seizure activity
- ⚠Significant cardiovascular events during administration
- ⚠Severe renal dysfunction or worsening kidney function
Contraindications
- ✕Epilepsy
- ✕Severe renal insufficiency
- ✕History of severe allergic reactions to porcine products
Quality Checklist
Good Signs ✓
- Clear amber solution from reputable source
- Room temperature storage ≤25°C
- Protected from light in original carton
- Authorized EVER Pharma distributor
Warning Signs !
- Some published studies have been retracted due to research misconduct; rely on independent meta-analyses
Bad Signs ✕
- Frozen product or improper storage—never freeze
- Mixing with incompatible solutions (amino acids, vitamins, cardiovascular medications)
References
Phase IIIb/IV RCT: patients with GCS 7-12 received 50 mL Cerebrolysin daily for 10 days + two additional 10 mL cycles; confirmed beneficial effects on overall outcome after moderate-severe TBI.
View on PubMed →Meta-analysis of 1,879 stroke patients showed NIHSS superiority of Cerebrolysin (MW 0.60, P < 0.0001); NNT = 7.7 for clinically relevant early neurological improvement.
View on PubMed →Meta-analysis of 1,779 patients found no significant benefit on mRS response (RR 1.33, P=0.28) or Barthel Index; concluded routine use for long-term stroke rehabilitation not supported.
View on PubMed →10 studies of 8,749 TBI patients; GOS improvement was statistically significant (mean difference 0.422, P = 0.000); mortality and length of stay were not significantly affected.
View on PubMed →6 RCTs in mild-to-moderate AD; Cerebrolysin significantly superior to placebo on ADAS-cog at 4 weeks (SMD -0.40, P=0.003) and CIBIC global clinical change at 4 weeks and 6 months.
View on PubMed →FAQs
Does Cerebrolysin actually work for stroke recovery or is the evidence mixed?
Evidence is mixed. Large meta-analysis of 1,879 stroke patients showed NIHSS (neurological function) superiority, but an independent analysis found no significant improvement in modified Rankin Scale (functional outcomes). Cerebrolysin appears to have early neurological benefits without clear long-term functional recovery advantage.
Is Cerebrolysin safe given some published studies have been retracted?
Yes, several Cerebrolysin studies were retracted due to research misconduct. However, well-conducted meta-analyses by independent researchers confirm safety and modest efficacy signals. Rely on meta-analyses and well-designed RCTs rather than individual studies, some of which have credibility issues.
How quickly should Cerebrolysin be started after stroke or TBI for best results?
Early administration within 72 hours shows better outcomes than delayed treatment. Acute stroke protocols use 20-50mL daily IV infusion for 10-21 days. TBI protocols use similar dosing for 7-30 days depending on severity. Earlier initiation appears critical for neuroprotective benefit.
Can I mix Cerebrolysin with other IV solutions, vitamins, or medications?
No. Official guidelines contraindicate mixing Cerebrolysin with amino acid solutions, cardiovascular medications, or vitamin solutions in the same IV infusion. Compatibility issues exist, so use dedicated IV lines. Flush with sodium chloride before and after administration per protocol.
